20,849 Shares in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Acquired by Capula Management Ltd

Capula Management Ltd acquired a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,849 shares of the biopharmaceutical company's stock, valued at approximately $685,000.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its position in shares of Agios Pharmaceuticals by 283.2% during the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock worth $2,017,000 after buying an additional 33,546 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Agios Pharmaceuticals by 15.1% in the third quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock worth $531,000 after purchasing an additional 1,570 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at $315,000. State Street Corp raised its stake in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after purchasing an additional 216,484 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in Agios Pharmaceuticals by 56.2% in the third quarter. XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company's stock worth $370,000 after purchasing an additional 2,996 shares during the period.

Analyst Ratings Changes

A number of research firms have commented on AGIO. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. HC Wainwright started coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price on the stock. Finally, StockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $56.57.

Remove Ads

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. The trade was a 4.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Stock Up 5.5 %

Agios Pharmaceuticals stock traded up $1.39 during mid-day trading on Friday, hitting $26.70. The company's stock had a trading volume of 592,295 shares, compared to its average volume of 710,897. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The stock's fifty day moving average price is $31.39 and its two-hundred day moving average price is $39.18. The stock has a market capitalization of $1.53 billion, a P/E ratio of 2.35 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.